Imatinib is a medication used to treat chronic myelogenous leukemia (CML). It belongs to a group of drugs called tyrosine kinase inhibitors that work by blocking certain proteins that signal cancer cells to multiply.

Nilotinib is a cancer medication that works similarly to imatinib. It is used to treat chronic myelogenous leukemia by blocking specific proteins that cause cancer cells to grow and spread.

Dasatinib is another medication in the tyrosine kinase inhibitor group used to treat chronic myelogenous leukemia. It works by stopping the growth of cancer cells by interfering with specific proteins that signal these cells to multiply.

Bosutinib is also a tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia. Like the other medications in this trial, it works by blocking certain proteins that promote cancer cell growth.

Chronic Myelogenous Leukemia (CML) – A type of blood cancer that begins in the bone marrow, causing the body to produce too many white blood cells. The disease typically develops slowly during its chronic phase, when the bone marrow and blood contain less than 10% immature white blood cells called blast cells. During this phase, patients may experience mild symptoms such as fatigue, weight loss, or enlarged spleen. The condition is characterized by the presence of an abnormal chromosome called the Philadelphia chromosome, which creates a faulty protein that leads to uncontrolled cell growth. The chronic phase is the initial, most manageable phase of CML, during which the disease progresses slowly and blood cells can still carry out their normal functions.